CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 41 enrolled
Drug / intervention
Cytosponge™device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03529669
NCT03529669N/ACompleted
CompareCT.gov

Evaluation of a Non-Endoscopic Immunocytological Device (Cytosponge™) for Post Chemo-radiotherapy Surveillance in Patients With Oesophageal Cancer -a Feasibility Study.

University of Oxford·interventional·Posted May 18, 2018·Updated Jul 25, 2022

In Brief

A clinical study evaluating Cytosponge™ for Oesophageal Cancer. Completed, enrolled 41 participants across 11 sites.

Detailed Summary

This is a feasibility study testing the use of the Cytosponge™ device in patients with known oesophageal cancer treated with pre-operative or definitive chemoradiation. All participants will receive one Cytosponge™ procedure at one time-point within 4-16 weeks after completion of chemoradiotherapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOesophageal Cancer
CountriesUnited Kingdom
CollaboratorsCentre for Statistics in Medicine, Cancer Research UK, University of Cambridge, Cambridge University Hospitals NHS Foundation Trust

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedMay 18, 2018
Enrollment StartApr 18, 2018
Primary CompletionJan 30, 2020
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 8.1 years ago

Interventions

Cytosponge™device

Cytosponge™ is a capsule-sized device which contains an expandable, spherical mesh which is attached to a string. The capsule dissolves in the stomach after swallowing, releasing the sponge which is then retrieved by gently pulling the string after five minutes. As the sponge is pulled out it collects the cells from the lining of the gullet.